BRPI0307679A2 - vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação. - Google Patents

vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação.

Info

Publication number
BRPI0307679A2
BRPI0307679A2 BRPI0307679A BR0307679A BRPI0307679A2 BR PI0307679 A2 BRPI0307679 A2 BR PI0307679A2 BR PI0307679 A BRPI0307679 A BR PI0307679A BR 0307679 A BR0307679 A BR 0307679A BR PI0307679 A2 BRPI0307679 A2 BR PI0307679A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
influenza
viruses
expressing
cell
Prior art date
Application number
BRPI0307679A
Other languages
English (en)
Inventor
Yoshihiro Kawaoka
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BRPI0307679A2 publication Critical patent/BRPI0307679A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0307679A 2002-02-13 2003-02-12 vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação. BRPI0307679A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35653802P 2002-02-13 2002-02-13
US43867903P 2003-01-07 2003-01-07
PCT/US2003/004233 WO2003068923A2 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors

Publications (1)

Publication Number Publication Date
BRPI0307679A2 true BRPI0307679A2 (pt) 2016-11-08

Family

ID=34380774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0307679A BRPI0307679A2 (pt) 2002-02-13 2003-02-12 vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação.

Country Status (13)

Country Link
US (3) US7226774B2 (pt)
EP (2) EP3009507B1 (pt)
JP (1) JP4430942B2 (pt)
KR (1) KR101113432B1 (pt)
CN (1) CN103540614B (pt)
AU (2) AU2003219745B8 (pt)
BR (1) BRPI0307679A2 (pt)
CA (1) CA2492097C (pt)
ES (2) ES2563402T3 (pt)
HU (2) HUE050222T2 (pt)
IL (2) IL163546A (pt)
MX (1) MXPA04007914A (pt)
WO (1) WO2003068923A2 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176021B2 (en) 2001-02-23 2007-02-13 Wisconsin Alumni Research Foundation Mutant cells with altered sialic acid
KR101113432B1 (ko) 2002-02-13 2012-02-29 위스콘신 얼럼나이 리서어치 화운데이션 인플루엔자 바이러스 벡터의 패키징을 위한 신호
CA2525953C (en) 2003-05-28 2023-10-10 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
EA200701097A1 (ru) 2004-11-19 2007-10-26 Висконсин Эламни Рисёч Фаундэйшн Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1917352A4 (en) * 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CN101563361B (zh) * 2005-10-19 2014-01-29 佛罗里达大学研究基金公司 能够感染犬科动物的流感病毒及其用途
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
KR100702034B1 (ko) * 2006-05-12 2007-03-30 삼성전자주식회사 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
WO2008147496A2 (en) * 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
WO2008148104A1 (en) * 2007-05-25 2008-12-04 Novavax, Inc. Novel vlps derived from cells that do not express a viral matrix or core protein
DK2155880T3 (en) * 2007-06-15 2016-12-05 Medicago Inc Modification of glycoproteinproduktion i plants
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009076778A1 (en) 2007-11-27 2009-06-25 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
AU2009267769B2 (en) 2008-07-08 2015-07-16 Medicago Inc. Soluble recombinant influenza antigens
NZ590351A (en) * 2008-07-18 2012-11-30 Medicago Inc HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
HUE039100T2 (hu) * 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
KR101773431B1 (ko) 2009-09-22 2017-09-12 메디카고 인코포레이티드 식물-유래 ｖｌｐ의 제조방법
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US10494613B2 (en) 2015-08-28 2019-12-03 Wisconsin Alumni Research Foundation (Warf) Generation of infectious influenza viruses from virus-like particles
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
EP4185601A4 (en) 2020-07-21 2024-10-30 Flugen, Inc. SKELETON OF THE INFLUENZA VIRUS
CN114908122B (zh) * 2021-02-07 2024-05-07 广州恩宝生物医药科技有限公司 一种用于表达外源蛋白的新型流感病毒载体及其构建方法
CN113069540B (zh) * 2021-03-15 2022-02-22 广州恩宝生物医药科技有限公司 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US6843996B1 (en) 1995-06-05 2005-01-18 Medimmune Vaccines, Inc. Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
US6271011B1 (en) * 1996-10-15 2001-08-07 The University Of Georgia Research Foundation, Inc. Pasteurella neuraminidase coding sequences and diagnostic methods
DE122008000035I1 (de) 1999-04-06 2009-05-20 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
ES2278621T5 (es) 1999-07-14 2011-02-02 Mount Sinai School Of Medicine Of New York University Reconstrucción in vitro de virus arn segmentados de polaridad negativa.
JP4927290B2 (ja) * 2000-04-14 2012-05-09 ウィスコンシン アルムニ リサーチ ファンデイション 変異イオンチャンネルタンパク質を含んで成るウイルス
US20040241139A1 (en) * 2000-07-20 2004-12-02 Gerd Hobom Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement
EP1201760A1 (en) 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
KR101113432B1 (ko) 2002-02-13 2012-02-29 위스콘신 얼럼나이 리서어치 화운데이션 인플루엔자 바이러스 벡터의 패키징을 위한 신호
EP1812564A2 (en) 2004-11-11 2007-08-01 Solvay Pharmaceuticals B.V. Defective influenza virus particles
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines

Also Published As

Publication number Publication date
US8298805B2 (en) 2012-10-30
HUE050222T2 (hu) 2020-11-30
KR20100065405A (ko) 2010-06-16
AU2003219745B2 (en) 2008-04-17
US20090311669A1 (en) 2009-12-17
CN103540614A (zh) 2014-01-29
JP4430942B2 (ja) 2010-03-10
HUE027448T2 (en) 2016-09-28
US20040002061A1 (en) 2004-01-01
US20070141699A1 (en) 2007-06-21
US7226774B2 (en) 2007-06-05
IL163546A (en) 2011-02-28
CN103540614B (zh) 2018-02-02
EP1572910A2 (en) 2005-09-14
KR101113432B1 (ko) 2012-02-29
CA2492097A1 (en) 2003-08-21
EP1572910A4 (en) 2008-01-23
AU2003219745A1 (en) 2003-09-04
WO2003068923A2 (en) 2003-08-21
CA2492097C (en) 2013-06-25
WO2003068923A3 (en) 2006-02-09
IL211324A0 (en) 2016-10-31
MXPA04007914A (es) 2004-10-15
ES2806412T3 (es) 2021-02-17
JP2005535288A (ja) 2005-11-24
ES2563402T3 (es) 2016-03-15
IL163546A0 (en) 2005-12-18
EP3009507A1 (en) 2016-04-20
AU2003219745B8 (en) 2008-10-09
EP3009507B1 (en) 2020-06-24
WO2003068923A9 (en) 2004-02-12
EP1572910B1 (en) 2015-12-02
US7585657B2 (en) 2009-09-08
AU2008203186A1 (en) 2008-08-07
AU2008203186B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
BRPI0307679A2 (pt) vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação.
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
BRPI0808104A2 (pt) Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante
WO2007085969A3 (en) Influenza vaccines containing hemagglutinin and matrix proteins
WO2005062820A3 (en) Multi plasmid system for the production of influenza virus
IL182225A (en) Nucleic acid compound encoding altered glycoprotein filvirus, DNA plasmid, recombinant virus or adenovirus containing the compound, a modified viral glycoprotein glycoprotein, vaccine or vaccine containing the compound or the glycoprotein alveolar compound and the glycoprotein
UA85536C2 (en) Viral antigens
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
ATE437222T1 (de) Alphavirus replikon-vektorsysteme
WO2007047459A8 (en) Rabies virus vector systems and compositions and methods thereof
WO2009082085A3 (en) Highly infectious nucleic acid molecules from pepper mottle virus and plant viral vector derived from the same
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
EA200600693A1 (ru) Пакующие клетки для рекомбинантных аденовирусов
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
IS7775A (is) DNA bóluefni sem umritar að minnsta kosti tvö óformgerð árprótín af vörtuveiru
EP1950307B8 (en) Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus spike protein
DK0552280T3 (da) Inhibering af viral replikation
ATE442441T1 (de) Virale expressionsvektoren für pflanzen
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
IL309038A (en) Temperature-controlled and self-replicating RNA constructs for viral diseases
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
MY147959A (en) Productivity augmenting protein factor, novel cell lines and uses thereof
WO2007019532A3 (en) Peptide aptamers that bind to the rep proteins of ssdna viruses
AU2022903672A0 (en) Chimeric viruses, chimeric viral proteins, and methods

Legal Events

Date Code Title Description
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A EXIGENCIA 6.7 PUBLICADA NA RPI 1871 DE 14/11/2006 POR TER SIDO INDEVIDA.

B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 60/356538 DE 13/02/2002 E US 60/438679 DE 07/01/2003 REIVINDICADAS NO PCT/US2003/004233, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 16/11/2004; CONTUDO, O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 13/10/2004 (60 DIAS APOS A ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISP

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]